Spec. Dr. (Specialist Dr.) BİLUN REŞİT AKYILDIZ

Dermatology

Medipol University Esenler Hospital
BİLUN REŞİT AKYILDIZ

Medical Areas of Interest

  •  Hair diseases
  •  Urticaria
  •  Warts
  •   Acne
  •   Itching
  •   Eczema
  •   Psoriasis
  •   Mole follow-up 
  •  Cosmetic dermatology
  • Minor surgical procedures

Highlights

Bilun Reşit Akyıldız is an experienced dermatologist with extensive clinical and international expertise, specializing in the diagnosis and treatment of a wide range of oncological diseases. In her clinical practice, she applies current treatment protocols based on evidence-based medicine principles and creates individualized treatment plans for each patient. 
She has extensive experience in the management of patients across different age groups and adopts a comprehensive approach, particularly in the care of older adults, by carefully considering coexisting medical conditions and each patient's overall clinical status. She effectively utilizes modern treatment methods and embraces a multidisciplinary working model.

Experiences

2021 - 2025

CERRAHPAŞA TIP FAKÜLTESİ

Educations

2020

ONDOKUZ MAYIS ÜNİVERSİTESİ, TIP FAKÜLTESİ

Memberships

  •  Turkish Dermatology Association 
  •  European Academy of Dermatology and Venerology (EADV)
     

Areas of Expertise

  •  Skin Diseases
  •  Venereal Diseases
     

Clinical Competencies

  •  Personalized treatment planning

Scientific Areas of Interest

  • Atopic dermatitis 
  • Hidradenitis suppurativa
     

Scientific Activities

  •  Book translation in the fields of Dermatology and Dermatological Surgery
  •  Participation in national congresses and scientific meetings
     

Additional Information

  • A multicenter, randomized, double-blind clinical trial evaluating the long-term efficacy, safety, and tolerability of subcutaneous secukinumab in participants with moderate to severe hidradenitis suppurativa.

     A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm Phase III clinical trial evaluating the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis (AD), who were receiving background topical corticosteroids and had demonstrated an inadequate response to previous biologic therapy or oral Janus kinase (JAK) inhibitor treatment.